Wrapping up Q2 earnings, we look at the numbers and key takeaways for the healthcare providers & services stocks, including AMN Healthcare Services (NYSE: AMN) and its peers.
The healthcare providers and services sector, from insurers to hospitals, benefits from consistent demand, generating stable revenue through premiums and patient services. However, it faces challenges from high operational and labor costs, reimbursement pressures that squeeze margins, and regulatory uncertainty. Looking ahead, an aging population with more chronic diseases and a shift toward value-based care create tailwinds. Digitization via telehealth, data analytics, and personalized medicine offers new revenue streams. Nonetheless, headwinds persist, including clinical labor shortages, ongoing reimbursement cuts, and regulatory scrutiny over pricing and quality.
The 39 healthcare providers & services stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 1.7% while next quarter’s revenue guidance was 1.6% above.
In light of this news, share prices of the companies have held steady. On average, they are relatively unchanged since the latest earnings results.
AMN Healthcare Services (NYSE: AMN)
With a network of thousands of healthcare professionals ranging from nurses to physicians to executives, AMN Healthcare (NYSE: AMN) provides healthcare workforce solutions including temporary staffing, permanent placement, and technology platforms for hospitals and healthcare facilities across the United States.
AMN Healthcare Services reported revenues of $673.2 million, up 2.3% year on year. This print exceeded analysts’ expectations by 7.2%. Overall, it was an incredible quarter for the company with a beat of analysts’ EPS estimates and revenue guidance for next quarter exceeding analysts’ expectations.
AMN Healthcare Services achieved the highest guidance raise of the whole group. Unsurprisingly, the stock is up 11.7% since reporting and currently trades at $34.41.
Is now the time to buy AMN Healthcare Services? Access our full analysis of the earnings results here, it’s free.
CVS Health (NYSE: CVS)
With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health (NYSE: CVS) operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary.
CVS Health reported revenues of $106.1 billion, up 7.3% year on year, outperforming analysts’ expectations by 6.7%. The business had an incredible quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 7% since reporting. It currently trades at $97.16.
Is now the time to buy CVS Health? Access our full analysis of the earnings results here, it’s free.
Weakest Q2: AdaptHealth (NASDAQ: AHCO)
With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ: AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.
AdaptHealth reported revenues of $740.3 million, up 12.7% year on year, falling short of analysts’ expectations by 12.6%. It was a disappointing quarter as it posted full-year revenue and EBITDA guidance missing analysts’ expectations significantly.
AdaptHealth delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 46.9% since the results and currently trades at $5.75.
Read our full analysis of AdaptHealth’s results here.
McKesson (NYSE: MCK)
With roots dating back to 1833, making it one of America's oldest continuously operating businesses, McKesson (NYSE: MCK) is a healthcare services company that distributes pharmaceuticals, medical supplies, and provides technology solutions to pharmacies, hospitals, and healthcare providers.
McKesson reported revenues of $105.4 billion, up 7.7% year on year. This number topped analysts’ expectations by 1.2%. Overall, it was a satisfactory quarter as it also recorded a beat of analysts’ EPS estimates.
The stock is down 1.2% since reporting and currently trades at $866.90.
Read our full, actionable report on McKesson here, it’s free.
Encompass Health (NYSE: EHC)
With a network of 161 specialized facilities across 37 states and Puerto Rico, Encompass Health (NYSE: EHC) operates inpatient rehabilitation hospitals that help patients recover from strokes, hip fractures, and other debilitating conditions.
Encompass Health reported revenues of $1.60 billion, up 9.6% year on year. This print beat analysts’ expectations by 1.8%. Overall, it was a strong quarter as it also put up an impressive beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.
The stock is up 11.4% since reporting and currently trades at $123.55.
Read our full, actionable report on Encompass Health here, it’s free.
Market Update
Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.
Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.
By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.
Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
